Abstract The aetiology of anti-factor VIII (FVIII) autoantibody formation in acquired haemophilia remains unknown. We hypothesised that encounter of antigenically different, allogeneic FVIII may challenge inhibitor formation after presentation on MHC class II. Eighteen consecutive cases with acquired haemophilia were enrolled (nine females, nine males). A control group comprised 50 male and 50 female healthy blood donors. The coding region of the FVIII gene and the HLA-DRB1 genotype were studied. The presentation of foreign FVIII variants on the patient's MHC class II alleles was predicted using SYFPEITHI algorithm. A rare FVIII variant (E2004K) was found in one patient with acquired haemophilia after massive transfusion; the 2004 K allele was predicted to be presented on the patient's HLA-DRB1*0101. Moreover, distribution of a polymorphism (D1241E) was significantly skewed comparing patients and controls. Three of three patients with transfusion-associated disease carried 1241D in homozygous or hemizygous form and were predicted to present 1241E (foreign), but not 1241D (self), on their HLA-DRB1*0301. Therefore, encounter of 1241E may result in the presentation of a new T cell epitope in these patients. The same conditions were not found in any patient with acquired haemophilia of other causes. The expected frequency in the general Caucasoid population undergoing transfusion is 3% to 4%. In conclusion, encounter of variant allogeneic FVIII presented on a suitable MHC background could be a risk factor for inhibitor formation.
Introduction
Acquired haemophilia is a rare disorder characterised by a sudden onset of severe subcutaneous, muscle or gastrointestinal bleeding. The haemostatic abnormality is due to autoantibodies inhibiting the activity of coagulation factor VIII (FVIII). In approximately 50% of cases, acquired haemophilia is associated with other autoimmune disorders, malignancy, the peripartum, medication or multiple transfusions [1] [2] [3] [4] . The pathogenesis of FVIII autoantibody formation in these cases as well as in idiopathic acquired haemophilia remains largely unknown.
Inhibitory antibodies against FVIII also occur as a complication of protein replacement therapy in congenital haemophilia A. FVIII antibodies occurring in cross-reactive material (CRM)-positive haemophilia A are sometimes specific against allogeneic (foreign, wild-type) FVIII [5] . However, these inhibitors more often cross-react with autologous (self, mutant) FVIII diminishing the patient's basal FVIII activity [6] [7] [8] [9] .
Current notion of inhibitor formation in CRM-positive haemophilia A is that FVIII missense mutations may alter T cell epitopes presented by the major histocompatibility complex (MHC) class II molecules [7] . This led us to hypothesize that also acquired haemophilia may sometimes result from difference between autologous and allogeneic FVIII. Such difference might induce an immune reaction after presentation of allogeneic FVIII on MHC class II. To prove the principle of such mechanism, we analysed the FVIII protein sequence and MHC class II genotype in affected patients.
Design and methods

Subjects
We enrolled 18 consecutive patients with acquired haemophilia who were admitted to Hannover Medical School (n= 12) or Frankfurt University Hospital (n=6) between 2001 and 2004. Acquired haemophilia was diagnosed due to (1) a recent onset of a bleeding history, (2) a FVIII activity in plasma below 50 international units (IU) dl −1 , and (3) a FVIII inhibitor ≥0.6 Bethesda units (BU) ml −1 measured by the Nijmegen-modified Bethesda assay [10] . Histories were taken by the authors or other physicians trained in disorders of haemostasis and a potential association with transfusion or pregnancy was evaluated in all cases. We also collected blood from the kindred of two patients with acquired haemophilia after delivery and from relatives of patient 5. A control group comprised 50 male and 50 female healthy blood donors (150 alleles). Informed consent was obtained from all study participants.
DNA-based assays
Genomic DNA was isolated from EDTA-anticoagulated blood using a DNA extraction kit (Amersham Pharmacia, Freiburg, Germany) and stored at -20°C. DNA concentration and purity was assessed by absorbance at 260 and 280 nm. Sequencing of the entire coding region and exon/intron boundaries of the FVIII gene was performed using the 310 ABI Prism Genetic Analyser and Big Dye Terminator sequencing chemistry (Perkin Elmer, Weiterstadt, Germany). The numbering of nucleotides is according to GenBank accession number M14113, of amino acid positions according to accession number P00451. Genetic analysis of the human leukocyte antigen (HLA)-DRB1 locus was performed using polymerase chain reaction with locus-specific primers and immobilised sequence-specific oligonucleotide probe methods.
Prediction of MHC-presented peptides
A motif pattern-based prediction algorithm together with the SYFPEITHI database [11] 
We then estimated how frequently the assumptions made for the proposed pathomechanism are fulfilled in the general population undergoing transfusion assuming the HLA-DRB1 phenotype frequency among West European Caucasoids as given in the Database of Blood and Kidney Donors of Essen, Germany (accessible at www.allelefrequencies. net): *0301 (0.22), *0701 (0.17) and *1501 (0.33).
Results
Patients
Clinical and laboratory data of the patients are summarised in Table 1 . Acquired haemophilia was associated with malignancy (n=5), delivery (n=3), transfusion (n=3) and bronchial asthma or chronic obstructive lung disease (n=2). Of the three patients, who developed acquired haemophilia after transfusion, one patient (no. 5) had first been massively transfused 7 years earlier because of traumatic liver rupture. Now, on the day before an elective wound revision, a slightly prolonged activated partial thromboplastin time (APTT; 41 s, reference range 33-40 s) was documented. During the next 13 days, 32 units of red blood cells, 20 units of fresh frozen plasma and one platelet aphaeresis concentrate were administered due to bleeding and an increasingly prolonged APTT was noted. The other two patients received multiple units of red blood cells because of bleeding after percutaneous coronary intervention (no. 13) and trauma (no. 17, who also had von Willebrand disease type 2A). The exact number was not reported by the referring hospitals. APTT prolongation was first documented 5 and 12 days after first transfusion, respectively.
E2004K missense mutation
In one patient (no. 5), a hemizygous missense mutation at nucleotide 6238 (G>A) was found causing a substitution in the A3 domain (E2004K). This mutation does not cause congenital haemophilia A as demonstrated by the patient's unremarkable bleeding history prior to the onset of disease and a FVIII activity >100% after eradication of the inhibitor. The mutation was inherited as it was found in a heterozygous state in the patient's mother (FVIII activity 196 IU dl −1 ) and in two of his three sisters (FVIII activity not determined). Mutations of this residue were not found in any of the 100 controls enrolled in this study and have not been reported in the haemophilia A database [12] . The patient developed acquired haemophilia after multiple transfusions. A peptide containing E2004 (the wild-type variant foreign to the patient) ranked among the top 1% of peptides predicted to be presented on the patient's MHC class II allele HLA-DRB1*0101.
D1241E polymorphism
A polymorphism was found at nucleotide 3951 (C>G) causing a substitution in the B domain (D1241E). Among 100 controls, the allelic frequency of 1241D and 1241E was 84% and 16%, respectively. Peptides containing 1241D or 1241E were predicted to be presented on HLA-DRB1 alleles *0701 (relative rank 1.1%) and *1501 (1.5%). Allele *0301 was predicted to present a peptide containing 1241E (1.8%), but not 1241D. Alleles *0101, *0401 and *1101 were predicted not to present peptides containing 1241D or E. We hypothesised that immunisation might happen in patients with either 1241D or 1241E in homozygous form (females) or hemizygous form (males) together with an HLA-DRB1 allele predicted to present the foreign variant. As shown in Table 2 , three of three patients with transfusion-associated disease were homozygous or hemizygous for 1241D (self) and were predicted to present 1241E (foreign) on HLA-DRB1*0301. In these patients, HLA-DRB1*0301 was the only HLA allele predicted to present 1241E. Therefore, transfusion of 1241E (foreign) is predicted to result in a new T cell epitope because 1241D (self) cannot be presented.
We hypothesised that encounter of foreign FVIII variants may also happen during feto-maternal transfusion in pregnancy. Three of three patients with post-partum disease were homozygous for 1241D. In one patient, HLA-DRB1*1501 was predicted to present both 1241D (self) and 1241E (foreign). The remaining two patients had HLA-DRB1 alleles for which prediction was not available. Thus, the hypothesised pathomechanism cannot be ruled out in these patients. In patients with acquired haemophilia due to other causes, data for prediction were complete in eight of 12. Six of eight patients were either heterozygous for D1241E or had HLA-DRB1 alleles predicted not to present the foreign variant. Two patients were hemizygous for 1241D or 1241E and had HLA-DRB1 alleles predicted to present both variants of the polymorphism.
We assumed that immunisation against 1241E is particularly likely in transfusion recipients who are homozygous or hemizygous for 1241D and carry HLA-DRB1*0301, because this MHC class II molecule is predicted to present 1241E, but not 1241D. We calculated the probability of this assumption met in West European Caucasoids assuming the frequency of 1241D in males (f 1241D =0.84) and 1241D/D in females f 1241D=D ¼ 0:84 Â 0:84 ¼ 0:70 À Á ; the phenotypic frequency of HLA-DRB1*0301 (f *0301 =0.22) and the probability of a 1241E phenotype in a single-donor blood product (p 1241E =0.21, see Design and methods):
Thus, the assumptions made above are expected to be fulfilled in 3% to 4% of the general Caucasoid population undergoing transfusion. In transfusion-associated acquired haemophilia, these assumptions were met in three of three cases.
Discussion
We hypothesised that inhibitor formation in acquired haemophilia may sometimes be challenged by allogeneic FVIII variants encountered by administration of blood products or fetomaternal transfusion. Our hypothesis was applicable in all patients with exposure to allogeneic FVIII and prediction of MHC presentation available: in three out of three transfusion-related and one out of three pregnancyrelated cases. In the remaining two pregnancy-related cases, the same mechanism cannot be ruled out because prediction of MHC presentation was not available. In one patient with transfusion-related acquired haemophilia we found an additional, rare non-haemophilic FVIII variant (E2004K) presented on the patient's MHC class II.
The probability of our results being a chance finding has been estimated using a control group. Concerning the E2004K variant, this mutation is exceptionally rare. The mutation introduces a major change in a T cell epitope, which is likely to elicit an immune response. Concerning the D1241E polymorphism, both variants were sufficiently frequent and some of the most prevalent MHC class II variants were capable of presenting. Therefore, alloimmunisation might be expected with a certain frequency in the general population undergoing transfusion. However, the epitope change introduced by the D1241E polymorphism seems to be minor since both amino acids are similar in charge and size. This may explain why most individuals undergoing transfusion do not develop a detectable immune response. It was striking that all individuals with transfusion-associated acquired haemophilia carried HLA-DRB1*0301. This allele was predicted to present 1241E, but not 1241D. Encounter of 1241E may result in a new T cell epitope in these patients, because the patient's self allele, 1241D, cannot be presented and central tolerance might not be achieved during T cell maturation in the thymus. In the general population, the same conditions are expected at a very low frequency. However, this frequency is still considerably higher compared to the incidence of acquired haemophilia. Similar to inhibitor formation in congenital haemophilia, the actual risk of inhibitor formation might be influenced by additional factors including immune response genes, danger signals and the dose of antigen encountered. The immune reaction resulting in acquired haemophilia is apparently both autoreactive (as evidenced by the patient's decreased FVIII activity) and alloreactive (as demonstrated by the lack of response to FVIII protein replacement). Our hypothesis of inhibitor formation through alloimmunisation implies a switch from an initially alloreactive immune response towards a response that is both alloreactive and autoreactive. Current notion of inhibitor formation in CRM-positive haemophilia A is that allogeneic FVIII-derived peptides presented on MHC class II trigger a specific, alloreactive CD4 T cell response [13] . Subsequently, armed CD4 T helper cells can stimulate reactive B cells to produce alloreactive antibodies. However, the normal B cell repertoire contains a broad spectrum of autoreactive B cells including anti-FVIII B cells [14] . As B and T cell epitopes may reside in different regions of a protein, armed alloreactive T cells can stimulate any B cell presenting the allogeneic T cell epitope, regardless of the B cell epitope. As a result, autoreactive B cells can be stimulated by alloreactive T cells (Fig.1 ). This mechanism is also known as determinant spreading from other autoimmune disorders [15] . Similar mechanisms might be at work in post-transfusion purpura, a syndrome characterised by sudden onset of thrombocytopenia after blood transfusion. Patients have been shown to be sensitised to allogeneic platelet antigens, most often HPA-1a. Pan-reactive platelet antibodies including autoantibodies have been detected in the acute phase of disease [16] indicating that a primarily alloreactive immune response resulted in loss of self tolerance. Another example is the development of factor V inhibitors in patients receiving topical bovine thrombin either directly or as a component of fibrin glue [17] . These preparations also contain bovine factor V and have been reported to frequently induce autoreactive antibodies against factor V [18] . Factor V inhibitors have also been reported following the use of human thrombin preparations containing human factor V [19] . Therefore, some of the many known factor V polymorphisms may be antigenically relevant in patients with appropriate MHC class II alleles and trigger inhibitory immune responses. Recently, the development of pure red cell aplasia has been reported due to erythropoietin autoantibodies in patients treated with recombinant human erythropoietin [20, 21] . Although glycosylation differences between the native and recombinant hormone are currently suspected to promote autoantibody formation [21] , it might be useful to look for rare erythropoietin variants in these patients.
In summary, our study suggests that primary structure variants of the FVIII protein presented on a suitable MHC class II background may trigger inhibitor formation after exposure to allogeneic FVIII. The mechanism suggested here may not only be relevant for acquired haemophilia. Generally, patients carrying variant or polymorphic proteins could develop autoreactive inhibitors after therapeutic administration of antigenically different proteins. 
